LKLisette Johanna Antonia Kogelman

Lisette Johanna Antonia Kogelman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lisette Johanna Antonia Kogelman has a total of 403 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Menstrual cycle phase length variation is associated with daily symptom burden

    by Lisette J.A. Kogelman, David Westergaard, Karina Banasik, Henriette Svarre Nielsen, Thomas Folkmann Hansen

    Menstrual symptoms vary across the cycle, yet most research assumes a normative 28-day cycle with fixed phase durations, obscuring the physiological relevance of natural cycle variation. Using the mcPHASES dataset, we characterised cycle and phase length variation across 96 menstrual cycles from 37 participants, with ovulation timing estimated from daily urinary luteinizing hormone measurements using a Bayesian hierarchical model, and examined associations with daily symptoms in a subset of 64 cycles from 35 participants with complete symptom data. Twelve physical, mental, and behavioural symptom domains were modelled using Bayesian ordinal regression, with posterior uncertainty in phase-length predictors propagated via a measurement error framework. Total cycle length was not associated with daily symptom burden, except sleep disturbances. By contrast, phase length decomposition revealed systematic associations across multiple domains: longer menstrual phase length was broadly associated with greater symptom intensity spanning physical, gastrointestinal, affective, and sleep domains; longer luteal phase duration was associated with greater fatigue and more frequent headaches, but lower sore breast intensity and lower stress; and longer follicular phase duration and later ovulation were each associated with greater sore breast intensity and more frequent mood swings. These associations require knowledge of actual ovulation timing and cannot be recovered from cycle length alone, indicating that the common assumption of a fixed 14-day luteal phase introduces systematic misclassification of hormonal exposure. Daily symptom intensity was also predominantly person-specific, with cycle phase explaining little of the between-person variance across most symptoms. These findings indicate that calendar-based phase assignment is insufficient for research and clinical assessment of hormone-sensitive conditions, and that person-specific baselines, rather than population-level phase averages, are needed for clinically meaningful symptom monitoring.

  • Open Access

    Effect of Hormonal Contraceptives on Circulating Biomarkers of Inflammation, Chemotaxis, Angiogenesis, and Vascular Stress

    by Bertram Kjerulff, Khoa Manh Dinh, Jens Kjærgaard Boldsen, Ulrik Schiøler Kesmodel, Joseph Dowsett, Susan Mikkelsen, Lisette J. A. Kogelman, Maria Didriksen, Christina Mikkelsen, Jakob Bay, et al.

    Hormonal contraceptive (HC) use is known to be associated with elevated CRP levels. However, evidence on the effect of HC on several circulating inflammatory biomarkers in healthy humans is limited. The aim of this study was to examine the association between hormonal contraceptives and circulating biomarker levels and differential cell counts. A cross‐sectional observational study design with biomarker measurements from 4,160 healthy females was used, coupled with registered HC prescriptions. We compared 752 high and low dose combined oral contraceptive (COC) users, 77 progestin‐only pill users, 417 levonorgestrel intrauterine device users, 65 hormonal therapy users, and 1,523 post‐menopausal women with a control group of 1,326 women below 50 years. Repeated differential cell counts from a different dataset of 16,231 females were analyzed for the effects of HC. Data were analyzed using various regression models. COC use was associated with higher vascular marker levels but lower chemokine levels. We found no association with progestin‐only use. The association with differential cell counts was limited for most HC types. This study emphasizes the widespread impact of HC on the immune and vascular systems and how the impact may differ between HC types. The biomarker associations found could be targets for elucidation in functional studies.


  • Open Access

    Genetic liability for endometriosis associates with pain, inflammatory, and metabolic traits: a polygenic score analysis

    by Juliane L Beauchamp, Karina Banasik, Lisette J Kogelman, David Westergaard, Dea F Skipper, Olafur Davidsson, Sisse R Ostrowski, Christina Mikkelsen, Christian Erikstrup, Mie T Bruun, et al.

    Purpose: Endometriosis is associated with pain, cardiometabolic, psychiatric, and immune comorbidities. We tested whether the genetic liability captured by an endometriosis polygenic risk score (PRS) extends to these comorbidities through shared pathways or operates independently of the disease. Methods: In 168,238 women and 155,304 men of European ancestry from two Danish genetic studies linked to national health registers, we constructed an endometriosis PRS using LDpred2 from an independent GWAS meta-analysis (23,112 cases, 429,677 controls). Entropy balancing with doubly robust adjustment addressed selection bias. Comorbidity analyses were performed in both sexes to distinguish shared from endometriosis-specific pathways. Results: The PRS was associated with endometriosis (OR 1.55 per SD, 95% CI 1.50–1.61; AUC 0.73) and with 20 of 29 comorbidities in women. Pain conditions (fibromyalgia, migraine, chronic back pain) and cardiometabolic conditions replicated in men, indicating shared pathways, whereas immune-mediated conditions associated in women only. Seventeen associations persisted in women without diagnosed endometriosis. High genetic risk was associated with increased healthcare utilisation and all-cause mortality (HR 1.05, 95% CI 1.01–1.10). Conclusion: The endometriosis PRS captures a pain-inflammatory-metabolic genetic axis operating in both sexes, indicating that the genetic liability extends beyond the uterine disease and providing a rationale for targeted investigation and risk stratification.

  • Open Access

    The burden of endometriosis on quality of life in Danish women: an analysis of the Danish Blood Donor Study

    by Lisette J. A. Kogelman, Dorte Rytter, Lone Hummelshoj, Karina Ejgaard Hansen, Ulrik Bak Kirk, Juliane Lyng Beauchamp, Jakob Thaning Bay, Mie Topholm Bruun, Nanna Brøns, Christian Erikstrup, et al.

    Background: Endometriosis is a complex condition with a wide range of comorbidities. It is widely underdiagnosed, with a diagnostic delay of 4 to 10 years, potentially leading to worsened disease progression and a higher burden of comorbidities affecting quality of life. Understanding the link between endometriosis and its comorbidities is essential for improving early detection of the disease. Methods: We analysed data from 953 women with a clinical diagnosis of endometriosis and 23,652 age-matched female controls enrolled in the Danish Blood Donor Study, using a case-control design. Participants completed one to four questionnaires covering a wide range of potential comorbidities; genetic data were available for a subset of participants. First, we compared the potential comorbidities between women with endometriosis and controls. Next, we investigated whether a polygenic score (PGS) for endometriosis was associated with those comorbidities. Lastly, we investigated whether women with a high genetic burden of endometriosis (highest PGS decile) experienced similar comorbidities to those diagnosed with endometriosis. Results: Women with endometriosis experienced challenges in conception, gastrointestinal symptoms, and disturbed sleep patterns, compared to age-matched controls. The endometriosis PGS showed to be a predictor for endometriosis (OR per unit PGS = 1.43, 95% CI = 1.32–1.55). Gastrointestinal symptoms were also nominally associated with the endometriosis PGS, suggesting shared genetic pathways. Women without a diagnosis of endometriosis but with a high genetic burden of endometriosis did not suffer from the same wide range of comorbidities as women diagnosed with endometriosis. Conclusions: Our findings highlight the complex genetic and clinical relationships between endometriosis and its comorbidities, emphasizing the need for future research investigating potential endometriosis subtypes.


  • Open Access

    Genome sequencing reveals the Adgrl3 ( ADGRL3 ) gene as a possible cause of cephalic hypersensitivity in the STA rat and migraine in humans

    by Brian Skriver Nielsen, Hongru Wang, Tanya Ramdal Techlo, Lisette Kogelman, Sarah Louise Christensen, Sanne Hage la Cour, Sabrina Prehn Lauritzen, Gordon Munro, Steffen Petersen, Marlene Danner Dalgaard, et al.

    Background: Migraine is a common primary headache disorder with a significant genetic component influencing its pathophysiology, in which the trigeminal system plays a central role. The spontaneous trigeminal allodynia (STA) inbred rat strain is a validated migraine model that exhibits a chronic cephalic hypersensitive phenotype, responsive to specific migraine treatments. The heritable STA trait presents a unique opportunity to dissect the genetic component of migraine. Methods: STA rats were backcrossed twice with wild-type (WT) Sprague–Dawley (SD) rats and whole-genome sequencing was performed on 47 rats exhibiting either the STA or WT phenotype. mRNA and protein expression analyses were conducted in the trigeminovascular system of both rats and humans. Based on data from the STA rats, we performed an F-SKAT (i.e. sequence kernel association test for family data) analysis to investigate a potential link between families with clustering of migraine and our findings from the STA rats. Results: Sequencing of STA rats revealed a risk locus near the gene for adhesion G protein-coupled receptor L3 ( Adgrl3 ). In humans, the ADGRL3 gene showed an increased burden of rare variants segregating with migraine in families with a clustering of the condition ( p = 0.046). We found similar associations between migraine and the ADGRL3 when expanding the analyses to a genome-wide analysis including rare variants from more than one million individuals with migraine. Expression analyses of rat and human tissues confirmed that Adgrl3 is expressed in the migraine-associated trigeminovascular system. Conclusions: In this translational study, ADGRL3 was associated with both cephalic hypersensitivity in STA rats and an increased burden of rare variants in humans with migraine. The gene was expressed in the trigeminovascular system, a central pathophysiological component of cephalic pain. ADGRL3 provides novel insights into the pathophysiology of chronic cephalic pain in migraine.


  • Open Access

    No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study

    by Inga Zalia Tummoszeit, Isa Amalie Olofsson, Mona Ameri Chalmer, Alexander Pil Henriksen, Bitten Aagaard, Søren Brunak, Mie Topholm Bruun, Maria Didriksen, Christian Erikstrup, Henrik Hjalgrim, et al.

    Objective: To determine the association between human leukocyte antigen (HLA) alleles and migraine, migraine subtypes, and sex‐specific factors. Background: It has long been hypothesized that inflammation contributes to migraine pathophysiology. This study examined the association between migraine and alleles in the HLA system, a key player in immune response and genetic diversity. Methods: We performed a case–control study and included 13,210 individuals with migraine and 86,738 controls. All participants were part of the Danish Blood Donor Study Genomic Cohort. Participants were genotyped and 111 HLA alleles on 15 HLA genes were imputed. We examined the association between HLA alleles and migraine subtypes, considering sex‐specific differences. Results: We found no association between HLA alleles and migraine, neither overall, nor in the sex‐specific analysis. In the migraine subtype analysis, three HLA alleles were associated with migraine without aura; however, these associations could not be replicated in an independent Icelandic cohort (2191 individuals with migraine without aura and 278,858 controls). Furthermore, we found no association between HLA alleles and migraine with aura or chronic migraine. Conclusion: We found no evidence of an association between the HLA system and migraine, suggesting that genetic factors related to the HLA system do not play a significant role in migraine susceptibility.

  • Open Access

    Metabolic Dysfunction in New‐Onset Idiopathic Intracranial Hypertension: Identification of Novel Biomarkers

    by Johanne Juhl Korsbæk, Rigmor Højland Jensen, Dagmar Beier, Elisabeth Arnberg Wibroe, Snorre Malm Hagen, Laleh Dehghani Molander, Matthew Paul Gillum, Katrine Svart, Thomas Folkmann Hansen, Lisette J.A. Kogelman, et al.

    Objective: Idiopathic intracranial hypertension (IIH) is a neurometabolic disease with an increasing incidence. The pathophysiology is unknown, but improvement of diagnosis and management requires discovery of novel biomarkers. Our objective was to identify such candidate biomarkers in IIH, and secondarily, test for associations between identified metabolites and disease severity.Methods: This is a prospective case–control study with collection of cerebrospinal fluid (CSF), serum, and clinical data from new‐onset, treatment‐naïve patients with IIH (n = 60). Patients were included consecutively from 2 tertiary headache centers in Denmark, and age, sex, and body mass index (BMI) ‐matched healthy controls (n = 35) were recruited. Clinical data were retrieved at ocular remission (n = 55). Samples were analyzed using non‐targeted mass spectrometry.Results: Serum sphingosine 1‐phosphate (S1P), adenosine, and glutamate were 0.46‐fold (q < 0.0001), 0.25‐fold (q = 0.0048), and 0.44‐fold (q < 0.0001) lower, respectively, in IIH. CSF stearoyl‐lysophosphatidylcholine (LysoPC‐18) and 2‐palmitoyl‐lysophosphatidylcholine (LysoPC‐16) were 0.42 (q = 0.0025) and 0.37 (q < 0.001) ‐fold lower. LysoPC‐18 was higher in patients with moderate–severe versus mild papilledema (p = 0.022). LysoPC‐18 correlated positively with retinal nerve fiber layer thickness (p = 0.0012, r = 0.42) and inversely with mean deviation on automated perimetry (p = 0.01, r = −0.35). Higher baseline serum S1P (p = 0.018) and lower CSF LysoPC‐16 (p = 0.003) were associated with optic nerve atrophy at ocular remission. Pathway analysis suggests dysregulated lipid metabolism and redox disturbances in new‐onset IIH.Interpretation: We identify perturbed metabolism in new‐onset IIH. S1P and LysoPC‐16 demonstrate potential prognostic value due to association with subsequent optic nerve atrophy. This association between specific, differential metabolites and outcome provides substantial evidence for novel biomarkers of clinical significance that should be the focus of further targeted studies. ANN NEUROL 2024;96:595–607


  • Open Access

    Genome-wide association study reveals a locus in ADARB2 for complete freedom from headache in Danish Blood Donors

    by Isa Amalie Olofsson, Ragnar P. Kristjansson, Ida Callesen, Olafur Davidsson, Bendik Winsvold, Henrik Hjalgrim, Sisse R. Ostrowski, Christian Erikstrup, Mie Topholm Bruun, Ole Birger Pedersen, et al.

    Headache disorders are the most common disorders of the nervous system. The lifetime prevalence of headache disorders show that some individuals never experience headache. The etiology of complete freedom from headache is not known. To assess genetic variants associated with complete freedom from headache, we performed a genome-wide association study of individuals who have never experienced a headache. We included 63,992 individuals (2,998 individuals with complete freedom from headache and 60,994 controls) from the Danish Blood Donor Study Genomic Cohort. Participants were included in two rounds, from 2015 to 2018 and in 2020. We discovered a genome-wide significant association, with the lead variant rs7904615[G] in ADARB2 (EAF = 27%, OR = 1.20 [1.13–1.27], p = 3.92 × 10−9). The genomic locus was replicated in a non-overlapping cohort of 13,032 individuals (539 individuals with complete freedom from headache and 12,493 controls) from the Danish Blood Donor Study Genomic Cohort (p < 0.05, two-sided). Participants for the replication were included from 2015 to 2020. In conclusion, we show that complete freedom from headache has a genetic component, and we suggest that ADARB2 is involved in complete freedom from headache. The genomic locus was specific for complete freedom from headache and was not associated with any primary headache disorders.


  • Open Access

    Reduced plasma calcitonin gene-related peptide level identified in cluster headache: A prospective and controlled study

    by Anja Sofie Petersen, Nunu Lund, Karl Meßlinger, Sarah Louise Christensen, Mads Barloese, Niklas Rye Jørgensen, Lisette Kogelman, Rigmor Højland Jensen

    Background: The role of calcitonin gene-related peptide (CGRP) in the cyclic pattern of cluster headache is unclear. To acquire biological insight and to comprehend why only episodic cluster headache responds to CGRP monoclonal antibodies, we examined whether plasma CGRP changes between disease states (i.e. bout, remission and chronic) and controls. Methods: The present study is a prospective case–control study. Participants with episodic cluster headache were sampled twice (bout and remission). Participants with chronic cluster headache and controls were sampled once. CGRP concentrations were measured in plasma with a validated radioimmunoassay. Results: Plasma was collected from 201 participants diagnosed with cluster headache according to the International Classification of Headache Disorders, 3rd edition, and from 100 age- and sex-matched controls. Overall, plasma CGRP levels were significantly lower in participants with cluster headache compared to controls ( p < 0.05). In episodic cluster headache, CGRP levels were higher in bout than in remission (mean difference: 17.1 pmol/L, 95% confidence interval = 9.8–24.3, p < 0.0001). CGRP levels in bout were not different from chronic cluster headache ( p = 0.266). Conclusions: Plasma CGRP is unsuitable as a diagnostic biomarker of cluster headache or its disease states. The identified reduced CGRP levels suggest that CGRPs role in cluster headache is highly complex and future investigations are needed into the modulation of CGRP and its receptors.


  • Top Cited Papers
    Open Access

    Rare variants with large effects provide functional insights into the pathology of migraine subtypes, with and without aura

    by Gyda Bjornsdottir, Mona A. Chalmer, Lilja Stefansdottir, Astros Th. Skuladottir, Gudmundur Einarsson, Margret Andresdottir, Doruk Beyter, Egil Ferkingstad, Solveig Gretarsdottir, Bjarni V. Halldorsson, et al.

    Migraine is a complex neurovascular disease with a range of severity and symptoms, yet mostly studied as one phenotype in genome-wide association studies (GWAS). Here we combine large GWAS datasets from six European populations to study the main migraine subtypes, migraine with aura (MA) and migraine without aura (MO). We identified four new MA-associated variants (in PRRT2, PALMD, ABO and LRRK2) and classified 13 MO-associated variants. Rare variants with large effects highlight three genes. A rare frameshift variant in brain-expressed PRRT2 confers large risk of MA and epilepsy, but not MO. A burden test of rare loss-of-function variants in SCN11A, encoding a neuron-expressed sodium channel with a key role in pain sensation, shows strong protection against migraine. Finally, a rare variant with cis-regulatory effects on KCNK5 confers large protection against migraine and brain aneurysms. Our findings offer new insights with therapeutic potential into the complex biology of migraine and its subtypes.